Riskpilot← Back to searchSign inGet full accessForward Pharma FA ApS
APSIn liquidationCVR 37281603Amaliegade 10Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik · NACE 721900Est. 2015— employees
Revenue 2022
DKK -32K
+289% vs 2021
EBITDA margin
100.0%
-289% vs 2021
Equity ratio
5.9%
Financial strength
Net profit 2022
DKK -36K
-213% vs 2021
| Revenue | DKK -32K | +289% |
| EBITDA | DKK -32K | -289% |
| Net profit | DKK -36K | -213% |
| Total assets | DKK 666K | -2% |
| Equity | DKK 39K | -48% |
| Employees | — | — |
Legal name
Forward Pharma FA ApS
CVR number
37281603
Legal form
Anpartsselskab
NACE code
721900 · Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Founded
3. december 2015
Share capital
DKK 50.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Amaliegade 10
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenue | -2.246 | -569 | -25 | -31 | -19 | -8 | -32 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -2.246 | -569 | -25 | -31 | -19 | -8 | -32 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -2.246 | -569 | -25 | -31 | -19 | -8 | -32 |
| Net financials | 49 | -4 | -3 | -3 | -4 | -3 | -4 |
| Profit before tax | -2.197 | -573 | -28 | -34 | -23 | -11 | -36 |
| Tax | -483 | -126 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -1.713 | -447 | -28 | -34 | -23 | -11 | -36 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Total assets | 1.443 | 782 | 739 | 715 | 697 | 683 | 666 |
| Equity | 419 | -29 | -56 | 10 | 87 | 75 | 39 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1.024 | 810 | 795 | 705 | 611 | 608 | 627 |
| Total debt | 1.024 | 810 | 795 | 705 | 611 | 608 | 627 |
EBITDA margin
-3212500.0%
This company
15.8%
Market median
-20332378% vs market
20162022
Equity ratio
5.9%
This company
38.2%
Market median
-85% vs market
20162022
Return on equity
-91.2%
This company
18.4%
Market median
-596% vs market
20162022
Net profit margin
-3583700.0%
This company
8.1%
Market median
-44243310% vs market
20162022
Asset turnover
-0.05×
This company
1.12×
Market median
-104% vs market
20162022
Debt / equity
15.96×
This company
0.62×
Market median
-2474% vs market
20162022
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2015-12-03 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PM Chief Executive Officer | Chief Executive Officer | 2015 | — | — |
CB Management | Management | 2017 | — | — |
TH Unofficial title | Unofficial title | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2015 | — | — | |
| Chairman | 2015 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Forward Pharma Operations ApS | Company | 100.0% | 100.0% | 2017 |
FORWARD PHARMA A/S | Company | 100.0% | 100.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Forward Pharma FA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peder Møller Andersen | Chief Executive Officer | 0 companies |
| Claus Bo Søndergaard Svendsen | Management | 0 companies |
| Thomas Hagen Weisbjerg | Unofficial title | 0 companies |
| Jakob Mosegaard Larsen | Board of Directors | 0 companies |
| Florian Schønharting | Chairman | 0 companies |